Immunexpress Analysis: $61M Raised
What is Immunexpress?
Immunexpress develops molecular diagnostic tools for sepsis detection by analyzing immune responses. Their SeptiCyte® RAPID technology provides results in one hour, significantly faster than traditional methods. The company aims to improve clinical outcomes and reduce healthcare costs associated with sepsis.
Location
425 Pontius Ave N, Seattle, Washington 98109, United States
Employees
11-50
Founded
2006
Product Features & Capabilities
- SeptiCyte® RAPID for rapid sepsis diagnosis
- Compatible with Biocartis Idylla™ platform
- Analyzes gene expression from whole blood
Use Cases
Diagnose sepsis in suspected patients within one hour; Provide actionable results for 100% of patients tested; Support clinicians in emergency and critical care settings; Aid in early identification to reduce mortality; Facilitate timely treatment decisions in hospitals
How much Immunexpress raised
Funding - $61M
Other Considerations
Serves healthcare stakeholders including medical professionals and payers; Focused on reducing mortality rates associated with sepsis; Aims to lower healthcare costs through early detection
See something that needs updating? Suggest edits to this profile.